Exploratory efficacy endpoints in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA)
Vaccine | 9 Feb 2017
C Webber, M Patton, S Patterson, B Schmoele-Thoma, SM Huijts and MJ Bonten
Abstract
The Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) assessed vaccine-type community-acquired pneumonia (VT-CAP) and vaccine-type invasive pneumococcal disease (VT-IPD) prevention with 13-valent pneumococcal conjugate vaccine (PCV13) in adults aged ⩾65years. We report vaccine efficacy (VE) of PCV13 for the remaining 23 exploratory endpoints and serotype distributions for pneumococcal CAP and IPD.
- Tweets*
- 1
- Facebook likes*
- 0
- Reddit*
- 0
- News coverage*
- 0
- Blogs*
- 0
- SC clicks
- 1
- Concepts
- Sputum, Haemophilus influenzae, Vaccine, Pneumococcal vaccine, Pneumococcal polysaccharide vaccine, Pneumococcal conjugate vaccine, Streptococcus pneumoniae, Pneumonia
- MeSH headings
- -
comments powered by Disqus
* Data courtesy of Altmetric.com